The gold-standard assay for measuring orexin deficiency in cerebrospinal fluid requires a lumbar puncture and radioactive materials. New findings could help advance testing alternatives for people with narcolepsy.
Samples from deceased brain donors reveal specific T-cells that can target orexin/hypocretin-expressing cells.
Harmony reveals new data showing pitolisant's safety at five times the highest labeled dose of WAKIX, along with updates on its orexin-2 agonist and long-term efficacy of pitolisant in IH.
New research reveals how orexin deficiency may paradoxically improve glymphatic function when NT1 patients are awake.
Read More
Alkermes today released topline results from the randomized double-blind treatment period of the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1.
Read More
A phase 3 readout is anticipated later this year.
Read More
Drug candidates aim to address the root cause of narcolepsy type 1—orexin deficiency—with some also being explored for narcolepsy type 2 and idiopathic hypersomnia.
Read More
Recent preclinical advancements have demonstrated the multi-target potential of DOXA compounds in redefining sleep-wake regulation and neuroprotection.
Read More
‘While GLP-1 therapies address part of the problem, they fail to target the neurological and systemic disruptions linked to the disease, including diabetes-associated neurological and sleep disorders.’
Read More
The approval moves NLS and Kadimastem closer to forming a combined Nasdaq-traded biotechnology company.
Read More
NLS Pharmaceutics has submitted three research abstracts to the 2025 Annual Meeting of the American Society of Clinical Psychopharmacology, with two focusing on sleep-related conditions.
Read More
The new CMO brings over 30 years of experience in neuroscience and drug development to Centessa as it advances its orexin receptor 2 agonist portfolio.
Read More
The $500,000 financing, part of a $1 million agreement, strengthens NLS’ capacity to complete its merger with Kadimastem, creating a combined Nasdaq-traded biotech company.
Read More
The proposed transaction will create a Nasdaq-traded biotechnology company with product candidates in advanced stages of clinical development.
Read More
NLS Pharmaceutics’ CEO provided updates on the company’s progress with its dual orexin receptor agonist platform for narcolepsy, financial restructuring, and its anticipated merger with Kadimastem Ltd.
Read More
Preclinical findings from NLS Pharmaceutics demonstrate the therapeutic potential of dual orexin receptor agonists for narcolepsy and neurological disorders.
Read More
The experimental framework is designed to explore the therapeutic potential of two first-in-class non-sulfonamide dual orexin receptor agonists using a validated orexin knockout mouse model of narcolepsy.
Read More
Centessa Pharmaceuticals has initiated a phase 2 trial of ORX750, an oral orexin receptor 2 agonist designed to treat narcolepsy type 1, type 2, and idiopathic hypersomnia.
Read More